Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said.

Last we heard, the Westborough, Massachusetts company raised $2 million of a $4 million Series A round in August 2012; president and CEO Neil Hayward told Mass High Tech that the funding came from Access BridgeGap Ventures, the now-defunct venture arm of Access Industries. Its major investor now – owning 65 percent of Exithera – is Israel investment group CBI, which is owned by Access Industries.

We’re sort of grasping at straws here until Hayward calls us back – but here’s a nice little precis of what the company’s up to, courtesy of CBI: